Interaction between Pantoprazole and Cefuroxime
Moderate
Absorption
| ID | DDInter1388 and DDInter335 |
| Interaction |
The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.
abdominal pain
allergic rhinitis
allergic alveolitis
amblyopia
Amnesia
anaphylactic reaction
anaemia
Anorexia
Anxiety
Aching joints
More
|
| Management | Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil may want to avoid using H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. An alternative antibiotic may be considered if these medications cannot be discontinued. |
| References | |
| Alternative for Pantoprazole |
A02B
|
| Alternative for Cefuroxime |
S01A
Trifluridine
Benzylpenicillin (sodium)
Sulfacetamide (ophthalmic)
Tetracycline (topical)
Neomycin (topical)
Chloramphenicol (otic)
Resorcinol (topical)
Chloramphenicol (ophthalmic)
Gentamicin (topical)
Lomefloxacin
Benzylpenicillin
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction:If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction:Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction:Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.